Two HER2-targeting ADCs, trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan, have been approved for clinical use by the U.S. Food and Drug Administration (FDA) for treatment of metastatic HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.